journal
Journals Expert Review of Molecular Dia...

Expert Review of Molecular Diagnostics

https://read.qxmd.com/read/38369939/the-diagnosis-of-central-nervous-system-infections-in-resource-limited-settings-and-the-use-of-novel-and-molecular-diagnostic-platforms-to-improve-diagnosis
#21
REVIEW
James Milburn, Rachita Suresh, Ronan Doyle, Joseph N Jarvis
INTRODUCTION: Central nervous system infections (CNSI) disproportionately affect individuals in low-resource settings where diagnosis is challenging; large proportions of patients never receive a confirmed microbiological diagnosis resulting in inadequate management and high mortality. The epidemiology of CNSI varies globally and conventional diagnostics deployed in resource-limited settings have significant limitations, with an urgent need for improved diagnostic strategies. AREAS COVERED: This review describes molecular platforms and other novel diagnostics used in the diagnosis of CNSI that are applicable to resource-limited settings...
March 2024: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38193169/rapid-and-reliable-testing-for-clinically-actionable-egfr-mutations-in-non-small-cell-lung-cancer-using-the-idylla-tm-platform-a-real-world-two-center-experience-in-greece
#22
JOURNAL ARTICLE
Kleita Michaelidou, Ioannis Karniadakis, Varvara Pantelaion, Chara Koutoulaki, Eleni Boukla, Konstantinos Folinas, Pantelis Dimaras, Maria A Papadaki, Anastasios V Koutsopoulos, Dimitrios Mavroudis, Christine Vourlakou, Konstantinos Mavridis, Sofia Agelaki
BACKGROUND: Limited information exists on epidermal growth factor receptor (EGFR) molecular epidemiology in Greece. Next-generation sequencing (NGS) is the recommended method for EGFR genotyping in NSCLC. The Idylla Biocartis platform is a fully automated system for actionable EGFR mutation detection. RESEARCH DESIGN AND METHODS: We describe the prevalence of EGFR mutations in NSCLC patients in two high-volume clinical centers in Greece and compare key methods used for their determination...
January 9, 2024: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38183228/molecular-biomarkers-of-diffuse-axonal-injury-recent-advances-and-future-perspectives
#23
REVIEW
Youyou Zhang, Zhaoyang Li, Hui Wang, Zhiyong Pei, Shuquan Zhao
INTRODUCTION: Diffuse axonal injury (DAI), with high mortality and morbidity both in children and adults, is one of the most severe pathological consequences of traumatic brain injury. Currently, clinical diagnosis, disease assessment, disability identification, and postmortem diagnosis of DAI is mainly limited by the absent of specific molecular biomarkers. AREAS COVERED: In this review, we first introduce the pathophysiology of DAI, summarized the reported biomarkers in previous animal and human studies, and then the molecular biomarkers such as β-Amyloid precursor protein, neurofilaments, S-100β, myelin basic protein, tau protein, neuron-specific enolase, Peripherin and Hemopexin for DAI diagnosis is summarized...
January 5, 2024: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38173401/we-have-reached-single-visit-testing-diagnosis-and-treatment-for-hepatitis-c-infection-now-what
#24
REVIEW
Jason Grebely, Susan Matthews, Louise M Causer, Jordan J Feld, Philip Cunningham, Gregory J Dore, Tanya L Applegate
INTRODUCTION: Progress toward hepatitis C virus (HCV) elimination is impeded by low testing and treatment due to the current diagnostic pathway requiring multiple visits leading to loss to follow-up. Point-of-care testing technologies capable of detecting current HCV infection in one hour are a 'game-changer.' These tests enable diagnosis and treatment in a single visit, overcoming the barrier of multiple visits that frequently leads to loss to follow-up. Combining point-of-care HCV antibody and RNA tests should improve cost-effectiveness, patient/provider acceptability, and testing efficiency...
January 4, 2024: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38166613/utilization-and-outcomes-of-the-21-gene-recurrence-score-in-de-novo-metastatic-breast-cancer
#25
JOURNAL ARTICLE
Shi-Ping Yang, Ke Liu, Yang Li, Guan-Qiao Li, Jia-Yi Li, Yu-Yi Lin, San-Gang Wu
BACKGROUND: Limited data exist regarding the utility and validity of the 21-gene recurrence score (RS) in patients with de novo metastatic breast cancer (dnMBC). This study aimed to investigate the practice patterns as well as associated survival outcomes based on 21-gene RS in dnMBC. RESEARCH DESIGN AND METHODS: The Surveillance, Epidemiology, and End Results Oncotype database was queried for women with hormone receptor-positive and Her2-negative dnMBC. RESULTS: A total of 153 patients were identified, including 62...
January 2, 2024: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38131180/molecular-and-epigenetic-mechanisms-governing-ocular-surface-squamous-neoplasia-opportunities-for-diagnostics
#26
JOURNAL ARTICLE
Bharat Gurnani, Kirandeep Kaur
INTRODUCTION: Ocular surface squamous neoplasia (OSSN) is the most common ocular malignancy; the pathophysiology is influenced by molecular, genetic, and epigenetic mechanisms. The incidence of OSSN is associated with the anatomy and physiology of the ocular surface, limbal stem cell configuration, limbal vulnerability, cancer stem cells, dysplasia, neoplasia, angiogenesis, invasion, and metastasis. The key etiological factors involved are human papillomavirus (HPV), human immunodeficiency virus (HIV), immunosuppression, p53 tumor suppressor gene, hypovitaminosis A, and failure of Deoxyribonucleic acid (DNA) repair mechanisms...
December 22, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38112537/advancements-in-protein-glycosylation-biomarkers-for-ovarian-cancer-through-mass-spectrometry-based-approaches
#27
JOURNAL ARTICLE
Jua Lee, Ji Eun Park, Daum Lee, Nari Seo, Hyun Joo An
INTRODUCTION: Ovarian cancer, characterized by metastasis and reduced 5-year survival rates, stands as a substantial factor in the mortality of gynecological malignancies worldwide. The challenge of delayed diagnosis originates from vague early symptoms and the absence of efficient screening and diagnostic biomarkers for early cancer detection. Recent studies have explored the intricate interplay between ovarian cancer and protein glycosylation, unveiling the potential significance of glycosylation-oriented biomarkers...
December 19, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38073533/how-our-molecular-understanding-of-the-pathogenesis-of-mycobacterium-ulcerans-infection-can-improve-diagnosis-of-buruli-ulcer
#28
EDITORIAL
Gerd Pluschke, Louisa Warryn
No abstract text is available yet for this article.
December 11, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38059597/the-challenges-and-potential-in-developing-microrna-associated-with-regeneration-as-biomarkers-to-improve-prognostication-for-liver-failure-syndromes-and-hepatocellular-carcinoma
#29
REVIEW
Oliver D Tavabie, Siamak Salehi, Varuna R Aluvihare
INTRODUCTION: Determining the need for liver transplantation remains critical in the management of hepatocellular carcinoma (HCC) and liver failure syndromes (including acute liver failure and decompensated cirrhosis states). Conventional prognostic models utilize biomarkers of liver and non-liver failure and have limitations in their application. Novel biomarkers which predict regeneration may fulfil this niche. microRNA are implicated in health and disease and are present in abundance in the circulation...
December 7, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38044883/progress-in-the-field-of-noninvasive-diagnostics-for-colorectal-cancer-a-systematic-review-for-the-accuracy-of-blood-based-biomarkers-for-detection-of-advanced-pre-cancerous-lesions
#30
REVIEW
Rishabh Goyal, Molla M Wassie, Jean Winter, Timothy Jh Lathlean, Graeme P Young, Erin L Symonds
BACKGROUND: Early detection of pre-cancerous adenomas through screening can reduce colorectal cancer (CRC) incidence. Fecal immunochemical tests are commonly used, but have limited sensitivity for pre-cancerous lesions. Blood-based screening may improve test sensitivity. This systematic review and meta-analysis was conducted to evaluate the accuracy of blood-based biomarkers for detection of advanced pre-cancerous lesions. RESEARCH DESIGN AND METHODS: We present the accuracy of blood-based biomarkers for detection of advanced pre-cancerous lesions...
December 4, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38009232/molecular-imaging-of-parp-in-cancer-state-of-the-art
#31
REVIEW
Luca Filippi, Luca Urso, Viviana Frantellizzi, Katia Marzo, Maria Cristina Marzola, Orazio Schillaci, Laura Evangelista
INTRODUCTION: Poly-ADP-ribose-polymerase inhibitors (PARPi), which exploit the processes of so-called 'synthetic lethality,' have been successfully implemented in oncological practice. However, not all patients respond to PARPi, and there is an unmet need for noninvasive biomarkers suitable for patient selection and monitoring during PARPi therapy. AREAS COVERED: The first clinical applications of molecular imaging with positron emission tomography/computed tomography (PET/CT) with [18F]-FluorThanatrace ([18F]-FTT) and [18F]-PARPi, highly effective PARP-ligands, in patients with several malignancies, (head and neck, ovarian, prostate and breast cancer) are covered, with a particular focus on its potential for pre-treatment selection and follow-up...
November 27, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/37999991/molecular-diagnostic-criteria-of-myeloproliferative-neoplasms
#32
REVIEW
Claire Andrews, Eibhlin Conneally, Stephen E Langabeer
INTRODUCTION: Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal hematopoietic stem cell neoplasms characterized by the driver mutations JAK2, CALR, and MPL. These mutations cause constitutive activation of JAK-STAT signaling, which is central to pathogenesis of MPNs. Next-generation sequencing has further expanded the molecular landscape allowing for improved diagnostics, prognostication, and targeted therapy. AREAS COVERED: This review aims to address current understanding of the molecular diagnosis of MPN not only through improved awareness of the driver mutations but also the disease modifying mutations...
November 24, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/37997281/a-charming-molecular-profile-in-the-wrong-tissue-the-pathologist-in-the-era-of-molecular-diagnostics-in-the-gastrointestinal-tract
#33
EDITORIAL
Paola Parente, Federica Grillo, Alessandro Vanoli, Luca Mastracci, Matteo Fassan
No abstract text is available yet for this article.
November 23, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/37991006/a-fast-track-to-fungal-diagnosis-the-potential-of-molecular-diagnostics-for-fungi-at-the-point-of-care
#34
EDITORIAL
Paul Trubin, Marwan Azar
No abstract text is available yet for this article.
November 22, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/37979075/synovial-biopsies-for-molecular-definition-of-rheumatoid-arthritis-and-treatment-response-phenotyping-where-can-we-improve
#35
JOURNAL ARTICLE
Francesco Salvatore Iaquinta, Felice Rivellese, Costantino Pitzalis
INTRODUCTION: The extensive knowledge gained in the cellular and molecular mechanisms underlying Rheumatoid Arthritis (RA) pathogenesis has led to therapeutic advances. However, up to 10-20% of patients fail to respond to multiple therapeutic agents being classified as multi-drugresistant. A key challenge moving forward will be the implementation of synovial biopsies in clinical practice to facilitate the shift from the current trial-and-error strategy toward new forms of clinical trials...
November 18, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/37970883/identification-of-a-novel-epigenetic-marker-for-typical-and-mosaic-presentations-of-fragile-x-syndrome
#36
JOURNAL ARTICLE
Camilla Pereira da Silva, Diego Camuzi, Adriana Helena Deliveira Reis, Andressa Pereira Gonçalves, Jussara Mendonça Dos Santos, Filipe Brum Machado, Enrique Medina-Acosta, Sheila Coelho Soares-Lima, Cíntia Barros Santos-Rebouças
BACKGROUND: Fragile X syndrome (FXS) is primarily due to CGG repeat expansions in the FMR1 gene. FMR1 alleles are classified as normal (N), intermediate (I), premutation (PM), and full mutation (FM). FXS patients often carry an FM, but size mosaicism can occur. Additionally, loss of methylation boundary upstream of repeats results in de novo methylation spreading to FMR1 promoter in FXS patients. RESEARCH DESIGN AND METHODS: This pilot study investigated the methylation boundary and adjacent regions in 66 males with typical and atypical FXS aged 1 to 30 years (10...
November 16, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/37966969/micrornas-in-preeclampsia
#37
EDITORIAL
Zacharias Fasoulakis, Aggeliki Kolialexi, Danai Mavreli, Marianna Theodora
No abstract text is available yet for this article.
November 15, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/37961916/a-case-for-non-coding-rna-as-a-suitable-biomarker-of-amyotrophic-lateral-sclerosis
#38
EDITORIAL
Greig Joilin, Majid Hafezparast
No abstract text is available yet for this article.
November 14, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/37947389/the-tumor-immune-microenvironment-in-pancreatic-cancer-and-its-potential-in-the-identification-of-immunotherapy-biomarkers
#39
REVIEW
Ryouichi Tsunedomi, Yoshitaro Shindo, Masao Nakajima, Kiyoshi Yoshimura, Hiroaki Nagano
INTRODUCTION: Pancreatic cancer (PC) has an extremely poor prognosis, even with surgical resection and triplet chemotherapy treatment. Cancer immunotherapy has been recently approved for tumor-agnostic treatment with genome analysis, including in PC. However, it has limited efficacy. AREAS COVERED: In addition to the low tumor mutation burden, one of the difficulties of immunotherapy in PC is the presence of abundant stromal cells in its microenvironment. Among stromal cells, cancer-associated fibroblasts (CAFs) play a major role in immunotherapy resistance, and CAF-targeted therapies are currently under development, including those in combination with immunotherapies...
November 10, 2023: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/37933807/current-and-emerging-biomarkers-for-ulcerative-colitis
#40
REVIEW
Jan K Nowak, Rahul Kalla, Jack Satsangi
INTRODUCTION: Ulcerative colitis (UC) is a chronic illness requiring lifelong management that could be enhanced by personalizing care using biomarkers. AREAS COVERED: The main biomarker discovery modalities are reviewed, highlighting recent results across the spectrum of applications, including diagnostics (serum anti-αvβ6 antibodies achieving an area under the curve [AUC] = 0.99; serum oncostatin M AUC = 0.94), disease activity assessment (fecal calprotectin and serum trefoil factor 3: AUC > 0...
November 7, 2023: Expert Review of Molecular Diagnostics
journal
journal
39742
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.